Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.38 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.38 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ACE | P12821 | 1/20 | 0.35 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.34 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL188132 | 1.00 | HSD17B10 (0.48) | HSD17B10ITGB3ITGA2BALOX15GNAI3 | |
| Hydrochloric Acid SCHEMBL25226809 | 0.98 | HSD17B10 (0.47) | HSD17B10ITGB3ITGA2BALOX15GNAI3 | |
| SCHEMBL2362299 | 0.87 | HSD17B10 (0.41) | HSD17B10ITGB3ITGA2BALOX15GNAI3 | |
| SCHEMBL29954077 | 0.87 | HSD17B10 (0.41) | HSD17B10ITGB3ITGA2BALOX15GNAI3 | |
| SCHEMBL2362301 | 0.87 | HSD17B10 (0.41) | HSD17B10ITGB3ITGA2BALOX15GNAI3 | |
| SCHEMBL29392309 | 0.84 | GNAI3 (0.39) | GNAI3GNAO1GNAI1SMN1; SMN2KDM4E | |
| SCHEMBL23291292 | 0.84 | HSD17B10 (0.56) | HSD17B10ITGB3ITGA2BALOX15ACE | |
| SCHEMBL1007625 | 0.82 | KDM4E (0.54) | GNAI3GNAO1GNAI1SMN1; SMN2KDM4E | |
| SCHEMBL18872667 | 0.81 | HSD17B10 (0.40) | HSD17B10SMN1; SMN2 | |
| SCHEMBL2718426 | 0.80 | GNAI3 (0.41) | GNAI3GNAO1GNAI1SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024063648-A1 | Platform and scaffold for FAP targeting agents | ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM (NL) | 2024-03-28 | — | — | WO | claimed |
| EP-4342890-A1 | PLATFORM AND SCAFFOLD FOR FAP TARGETING AGENTS | Erasmus University Rotterdam Medical Center (NL) | 2024-03-27 | — | — | EP | claimed |
| EP-4342890-A1 | PLATFORM AND SCAFFOLD FOR FAP TARGETING AGENTS | Erasmus University Rotterdam Medical Center (NL) | 2024-03-27 | — | — | EP | disclosed |
| WO-2023229458-A1 | RADIOISOTOPE LABELED SSTR2-AGONISTS WITH LINKERS | ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM (NL) | 2023-11-30 | — | — | WO | disclosed |
| EP-4282439-A1 | RADIOISOTOPE LABELED SSTR2-AGONISTS WITH LINKERS | Erasmus University Rotterdam Medical Center (NL) | 2023-11-29 | — | — | EP | disclosed |
| EP-2252628-B1 | BOMBESIN ANALOG PEPTIDE ANTAGONIST CONJUGATES | UNIVERSITÄTSSPITAL BASEL (CH) | 2016-12-28 | — | — | EP | disclosed |
| US-9035023-B2 | Bombesin analog peptide antagonist conjugates | Piramal Imaging, SA (CH) | 2015-05-19 | — | — | US | disclosed |
| US-20110097266-A1 | Bombesin Analog Peptide Antagonist Conjugates | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-04-28 | — | — | US | disclosed |
| EP-2100900-A1 | Bombesin analog peptide antagonist conjugates | Universitätsspital Basel (CH) | 2009-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110097266-A1 | Bombesin Analog Peptide Antagonist Conjugates | BRS3, VIP, GRPR | HSD17B10 4724/4885ITGB3 2566/4885ITGA2B 1764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.